Compare Cytokinetics Inc (CYTK) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Gold Fields Limited — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Gold Fields Limited trades at $37.31 (market cap $31.87B). The key difference: Gold Fields Limited is far larger — about 3.7× Cytokinetics Inc's market cap, and Gold Fields Limited pays a 6% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Gold Fields Limited for 49 Days on average.
| CYTK | GFI | |
|---|---|---|
Market Cap | $8.62B | $31.87B |
Volume | 2,594,626 | 4,169,651 |
Sector | Health | Basic Materials |
52-Week High | $87.26 | $61.52 |
52-Week Low | $54.76 | $31.25 |
Typical Hold Time | 19 Days | 49 Days |
Enterprise Value | $8.72B | $32.47B |
Dividend Yield | — | 6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Gold Fields (GFI) trades at $35.05, down 3.1% amid market reaction to its rejected $27 billion bid for Northern Star. The stock shows a bearish technical signal with key support at $34-$35, while fundamentals remain strong with a 40.76% net margin and low P/E of 7.3. Recent earnings saw mixed results, with one beat and three misses against expectations.
The outlook is balanced: robust cash flow and high profitability support upside toward the $52.75 analyst target, but acquisition uncertainty and technical weakness pose near-term risks. Investor sentiment is cautious pending clarity on M&A strategy and capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
